No Data
US Stock MarketDetailed Quotes
PODD Insulet
Watchlist
192.190
+3.100+1.64% Close 12/01 16:00 ET
192.1900.0000.00%
Post 16:31 ET
192.500High185.870Low928.37KVolume
188.620Open189.090Pre Close176.63MTurnover1.34%Turnover Ratio111.74P/E (TTM)13.42BMarket Cap335.91052wk High2745.57P/E (Static)69.83MShares125.82052wk Low22.09P/B13.36BFloat Cap335.910Historical High--Dividend TTM69.49MShs Float2.570Historical Low--Div YieldTTM3.51%Amplitude190.259Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Insulet Company
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
U.S. Omnipod884.8M67.79%
International Omnipod363M27.81%
Drug Delivery57.5M4.41%
News
US Market Movers & Shakers in November: AFRM, ROKU, COIN, SQ and More
SCYNEXIS And 5 Other Stocks Have High Sales Growth And An Above 3% Return on Equity
(VIANEWS) – SCYNEXIS (SCYX), Consolidated Water Co. Ltd. (CWCO), Insulet (PODD) are the highest sales growth and return on equity stocks on this list.
Insulet to Present at Upcoming Investor Conferences
Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that management will present at two upcoming investor
Comments
Three things to watch this week: inflation, OPEC+reaction and insulin stocks
Inflation data is on watch and expected to fall in Australia and the US. But expect smart money to flow into healthcare stocks as job growth is slowing and surplus income is falling. We cover healthcare stocks to maybe jab into your portfolio. Plus, the potential OPEC+ meeting outcomes with stocks to watch given the oil price is in 'oversold' territory'
1- US inflation to fall under the Fed's target. Wow. Australia's inf...
1- US inflation to fall under the Fed's target. Wow. Australia's inf...
19
Concerns about potential impacts of GLP-1 drugs on the demand for diabetes device therapies may be misplaced, as illustrated by strong Q3 results from diabetes tech leaders like Abbott, Dexcom, and Insulet.
Analysts express optimism over Insulet's robust fundamentals, despite Raymond James reducing their price target. They also increased their revenue estimates, spotlighting Insulet as a rising star in medical technology.
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--